Compare AHT & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHT | DYAI |
|---|---|---|
| Founded | 2003 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 17.0M |
| IPO Year | 2003 | 2026 |
| Metric | AHT | DYAI |
|---|---|---|
| Price | $1.88 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.6K | ★ 131.5K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $1,502,759,000.00 | $3,090,345.00 |
| Revenue This Year | N/A | $113.16 |
| Revenue Next Year | N/A | $94.92 |
| P/E Ratio | $2.66 | ★ N/A |
| Revenue Growth | ★ 5.03 | N/A |
| 52 Week Low | $1.74 | $0.34 |
| 52 Week High | $5.29 | $1.60 |
| Indicator | AHT | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 16.45 | 34.77 |
| Support Level | N/A | $0.34 |
| Resistance Level | $3.20 | $0.50 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 14.67 | 8.80 |
Ashford Hospitality Trust Inc is a real estate investment trust (REIT) operating in the hotel lodging industry. The company's portfolio consists of upscale and upper upscale full-service hotels, with its investment focused on acquiring and investing in upper upscale full-service hotels in the United States that have revenue per available room (RevPAR) generally less than twice the U.S. national average, through direct real estate ownership as well as equity and debt investments. Its hotel properties are mainly branded under internationally recognized names such as Hilton, Hyatt, Marriott, and InterContinental Hotels Group. It operates through a single reportable business segment, direct hotel investments, which involves owning hotel properties through acquisitions or new development.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.